Author:
Moeed Abdul,Bilal Zoha,Batool Fizzah,Batool Zaidi Asma,Arsalan Jamil Muhammad,Surani Salim
Abstract
Ventilator-associated pneumonia accounts for 60% of healthcare-associated infection deaths. It results from invasion of the lower respiratory tract by microorganisms and affects patients 48 hours after they have been intubated and have received mechanical ventilation. Prompt diagnosis using a combination of clinical, radiographic, microbiological, and laboratory assessment can help prevent exacerbation of symptoms and provide immediate treatment. Usage of antibiotics for therapy has proven clinically useful; however, emerging resistance of microorganisms to these medications has been continuously evolving. This article focuses on amikacin and how its emerging role in treating VAP has improved patient outcomes and increased their chances of recovery with minimal adverse effects.